OliX Pharmaceuticals, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2010-02-26
- Employees
- 74
- Market Cap
- -
- Website
- http://www.olixpharma.com
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
Phase 1
Recruiting
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Genetic: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Olix Pharmaceuticals, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05643118
- Locations
- 🇺🇸
California Retina Consultants, Santa Maria, California, United States
🇺🇸University Retina, Oak Forest, Illinois, United States
🇺🇸The Retina Institute, Saint Louis, Missouri, United States
Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Olix Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04877756
- Locations
- 🇺🇸
Miami Dermatology & Laser Research, LLC, Miami, Florida, United States
🇺🇸Paddington Testing Co, Inc., Philadelphia, Pennsylvania, United States
🇺🇸Miami Plastic Surgery, Miami, Florida, United States
A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Olix Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03569267
- Locations
- 🇬🇧
Covance Clinical Research Unit (CRU) Ltd., Leeds, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath